Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
October 8, 2008
Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
Analysis of: Genentech Set Back by Cancer-Drug Study | online.wsj.com
Author: GLG Expert Contributor
The primary goal was improved survival- NOT REACHED!!
October 6, 2008
Government Intervention is Here: Pharma had better get use to it....
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: GLG Expert Contributor
"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.
October 3, 2008
Radon & Lung cancer: Outside of Uranium Mines is it Relevant???
Analysis of: Protecting a Home From Silent Threat | www.nytimes.com
Author: GLG Expert Contributor
Radon is responsible for about 15% on lung cancer deaths in the US??
October 2, 2008
Idera Pharma: is there room for another agent in recurrent renal cell ca??
Analysis of: Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma | www.pipelinereview.com
Author: GLG Expert Contributor
Apparently Merck has an interest in this compound and it is in trial in combination in other neoplasms.
September 30, 2008
Epo & Stroke: The chickens coming home to roost.
Analysis of: F.D.A. Reviewing Deaths in Anemia Drug Study | www.nytimes.com
Author: GLG Expert Contributor
Epo (J & J's version) increased mortality when given to patients with a new stroke in an effort to improve brain function. What will this lead too?? 
September 29, 2008
Oh, Good, Not only won't seniors be able to understand it; they won't be able to afford it?
Analysis of: Medicare Drug Premium on Rise | online.wsj.com
Author: GLG Expert Contributor
Costs for Medicare part D are going up 31%
September 26, 2008
Molecular profiles in lung cancer: THE FUTURE IS HERE....
Analysis of: Lung Cancer | content.nejm.org
Author: GLG Expert Contributor
Clinical trials are being built around determining which molecular profiles require what therapy. It's here!!
September 25, 2008
Tomotherapy, Protons, Short Course Breast RT - ASTRO 2008
Analysis of: Hospitals Look to Nuclear Tool to Fight Cancer | www.nytimes.com
Author: GLG Expert Contributor
Tomotherapy may do well after all with newer bells and whistles introduced at ASTRO 2008. Protons are likely to die leaving investors with a huge bill and dwindling ROI. Short course breast radiotherapy is not worth the risk.
September 24, 2008
Lilly to Disclose Payments to Doctors: What a revolting development this is!
Analysis of: Lilly to Disclose Payments to Doctors | online.wsj.com
Author: GLG Expert Contributor
It will become public knowledge what Doctors are paid by Lilly for advice, lectures and other services.
September 23, 2008
3 week radiation for breast cancer: What is the cosmetic end result?
Analysis of: Shorter Radiation for Cancer of the Breast | www.nytimes.com
Author: GLG Expert Contributor
Results are identicle (3 weeks v 5 in post lumpectomy radiation?)

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 1024

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-11T13:45:17.197